Product Details
| Product Name:
Razuprotafib |
CAS No.:
1008510-37-9 |
| Purity:
99.76% |
Supply Ability:
10g |
| Release date:
2026/04/20 |
Product Introduction
Bioactivity
| Name | Razuprotafib |
| Description | Razuprotafib (AKB-9778) is a protein tyrosine phosphatase ? (HPTP?) inhibitor with an IC50 of 50 nM. It effectively activates Tie-2 and provides protection against acute kidney injury. |
| In vitro | Razuprotafib inhibits the phosphatase activity of VE-PTP with an IC50 of 17 pM.
Razuprotafib inhibits the phosphatase PTP1B with an IC50 of 780 nM.
Razuprotafib inhibits HPTPη (IC50 = 36 pM) .
Razuprotafib inhibits HPTPγ (IC50 = 100 pM).
Razuprotafib 0.17 to 50 μM HUVEC 10 minutes in WB
concentration-dependent phosphorylation of TIE2 and downstream components of the TIE2 signaling pathway, including eNOS, AKT, and ERK. |
| In vivo | Rho-VEGF–transgenic mice s.c. injection 20 mg/kg 12 hours promotes phosphorylation of TIE2 in retinal endothelial cells
Rho-VEGF mice s.c. injection 10-20 mg/kg twice daily for 7 days suppresses subretinal neovascularization. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.82 mM), Sonication is recommended.
DMSO : 150 mg/mL (255.67 mM), Sonication is recommended.
|
| Keywords | Tie-2 | Razuprotafib | Phosphatase | nephropathy | kidney | injury | Inhibitor | inhibit | HPTP? | diabetic | AKB9778 | AKB 9778 | acute |
| Inhibitors Related | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | Idoxuridine | Regorafenib | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | CaMKP Inhibitor | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | L-Ascorbic acid 2-phosphate | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Glycometabolism Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States